NCATS Strategic Planning Dorit Zuk, Ph.D. Director, OPCS A NCATS Council/ CAN Review Board Meeting eptember 3 rd , 2015 S
2
3
Strategic Planning Process Timeline S mall group Dec 2014-Apr 2015 discussions with staff Focus groups Aug 2015 develop RFI topics Publish RFI and End-Sep 2015 S trategic Plan website Conduct Town Hall Oct-Nov 2015 webinars Analyze stakeholder Dec 2015-Jan 2016 feedback Update Jan 2016 Council/ CAN RB Draft, review and Spring 2016 publish S trategic Plan
Stage 1 – Internal NCATS Discussion • S mall group discussions with all NCATS staff about NCATS ’ vision and foundational strategy Dec 2014-April 2015: 27 meetings, 252 staff • Feedback analysis underway • Will inform the development of the strategic plan 5
Stage 2 – Gathering Feedback from External Stakeholders S takeholders include among others: • Patients and members of the health advocacy community Basic, translational and clinical scientists at universities and research institutions Biotechnology and pharmaceutical industry members NIH colleagues Other government agencies (e.g., FDA, EP A, DoD) Policy-makers and funders As well as the general public • August - calls with NCATS staff and Council/ CAN RB members to develop the key strategic planning topics 6
Proposed Thematic Areas • Improving t he Drug Development Process • Pre-Clinical Innovat ion: Test ing & Predict ive Models • Repurposing Drugs • Re-Engineering t he Clinical & Translat ional Process • Accelerat ing & S upport ing Rare Diseases Research • Part nerships wit h S t akeholder Groups Obviously - overlap among t he areas. Feedback will be int egrat ed. Cont inuing t he discussion t oday… 7
Improving the Drug Development Process S ome possible RFI topics raised on call: Import ance of int er-operabilit y of bioinformat ic systems Int egrat ing pat ient dat a int o pre-clinical research Focus on t he precompet it ive space Expanding t herapeut ic modalit ies 8
Pre-Clinical Innovation: Testing & Predictive Models • S ome possible RFI topics raised on call: Approximat ing t he human condit ion Range of dat a needed for robust models Innovat ive mechanisms for dat a collect ion and analysis Engaging pat ient communit y in st udy design 9
Re-Engineering the Clinical & Translational Process • S ome possible RFI topics raised on call: Connect ing research and researchers along t he t ranslat ional science spect rum (“ de-siloizing” ) Measuring innovat ion in t ranslat ion S killset s and core compet encies needed in t ranslat ional science Defining and developing clinical informat ics 10
Repurposing Drugs • S ome possible RFI topics raised on call: S yst emat ic approaches Innovat ive part nerships t o facilit at e repurposing Involving t he communit y in repurposing effort s 11
Accelerating & Supporting Rare Diseases Research S ome possible RFI topics raised on call: Examinat ion of commonalit ies Defining rare diseases in an ‘ omics era Engagement of new part ners Pat ient -driven research 12
Partnerships with Stakeholder Groups S ome possible RFI topics raised on call: Engaging wit h t he pat ient communit y: a bi- direct ional process Nat ure of t he “ on-ramp” Innovat ive part nership models Modern communicat ion and educat ional t ools 13
Other Thematic Areas? 14
What we need next from Council/CAN RB • Please send any additional comments on key topics/ questions for stakeholder engagement in the next 10 days • When released, publicize and encourage your networks to respond to RFI and to participate in subsequent Town Hall webinars • Provide your own feedback 15
“It’s a Team Sport” NCATS S trategic Planning Team Penny Christine Taylor Cindy Megan Burgoon Cutillo McConnell Cowles Gilliland • 250+ NCATS staff who participated in small group discussions • Council and CAN Review Board members 16
Recommend
More recommend
